Literature DB >> 14642969

The dopamine D4 receptors and mechanisms of antipsychotic atypicality.

Albert H C Wong1, Hubert H M Van Tol.   

Abstract

The dopamine D4 receptor (D4) is a target for most common neuroleptic medications. After its initial discovery, it was found to possess the highest affinity of all dopamine receptor subtypes for the archetypical, atypical, antipsychotic clozapine. Nevertheless, initial clinical trials have not provided evidence that this receptor is a primary target for antipsychotic drugs. Considering the accumulated in vivo evidence that at least a subgroup of psychotic patients have altered dopamine signaling, all dopamine receptor subtypes likely contribute to the phenotypic expression of schizophrenia. New insights into the function of this receptor and its role in the modulation of excitatory signaling support the view that this dopamine receptor may affect attention and cognition. In this review, the authors outline some recent developments that provide insight into D4 receptor physiology, function and its possible relationship to schizophrenia treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642969     DOI: 10.1016/j.pnpbp.2003.09.005

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  16 in total

1.  Association between a synaptosomal protein (SNAP-25) gene polymorphism and verbal memory and attention in patients with endogenous psychoses and mentally healthy subjects.

Authors:  V E Golimbet; M V Alfimova; I K Gritsenko; T V Lezheiko; O M Lavrushina; L I Abramova; V G Kaleda; A N Barkhatova; A V Sokolov; R P Ebstein
Journal:  Neurosci Behav Physiol       Date:  2010-05

Review 2.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 3.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Authors:  Peter Heusler; Liesbeth Bruins Slot; Isabelle Rauly-Lestienne; Christiane Palmier; Stéphanie Tardif; Amélie Tourette; Marie-Christine Ailhaud; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-06       Impact factor: 3.000

Review 6.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

7.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; David Scheibal; Emily Hahn; Sharon Shiraga; Eleanor Zamora-Paja; Judah Farahi; Sanjaya Saxena; Edythe D London; James T McCracken
Journal:  Arch Gen Psychiatry       Date:  2006-07

Review 8.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

9.  Severe parkinsonism under treatment with antipsychotic drugs.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Sermin Toto; Alexandra Neyazi; Barbara Däubl; Susanne Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-23       Impact factor: 5.270

10.  ADHD candidate gene (DRD4 exon III) affects inhibitory control in a healthy sample.

Authors:  Ulrike M Krämer; Nuria Rojo; Rebecca Schüle; Toni Cunillera; Ludger Schöls; Josep Marco-Pallarés; David Cucurell; Estela Camara; Antoni Rodriguez-Fornells; Thomas F Münte
Journal:  BMC Neurosci       Date:  2009-12-20       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.